Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry

Research output: Contribution to journalArticlepeer-review

Authors

  • Jean-Yves Le Heuzey
  • Bettina Ammentorp
  • Harald Darius
  • Raffaele De Caterina
  • Richard John Schilling
  • Josef Schmitt
  • José Luis Zamorano

Colleges, School and Institutes

Abstract

Due to improved implementation of guidelines, new scoring approaches to improve risk categorisation, and introduction of novel oral anticoagulants, medical management of patients with atrial fibrillation (AF) is continuously improving. The PREFER in AF registry enrolled 7,243 consecutive patients with ECG-confirmed AF in seven European countries in 2012-2013 (mean age: 71.5 ± 10.7 years; 60.1% males; mean CHA2DS2-VASc score: 3.4). While patient characteristics were generally homogeneous across countries, anticoagulation management showed important differences: the proportion of patients taking vitamin K antagonists (VKAs) varied between 86.0% (in France) and 71.4% (in Italy). Warfarin was used predominantly in the UK and Italy (74.9% and 62.0%, respectively), phenprocoumon in Germany (74.1%), acenocoumarol in Spain (67.3%), and fluindione in France (61.8 %). The major sites for international normalised ratio (INR) measurements were biology laboratories in France, anticoagulation clinics in Italy, Spain, and the UK, and physicians' offices or self-measurement in Germany. Temporary VKA discontinuation and bridging with other anticoagulants was frequent (at least once in the previous 12 months for 22.9% of the patients, on average; ranging from 29.7% in Germany to 14.9% in the UK). Time in therapeutic range (TTR), defined as at least two of the last three available INR values between 2.0-3.0 prior to enrolment, ranged from 70.3% in Spain to 81.4% in Germany. TTR was constantly overestimated by physicians. While the type and half-lives of VKA as well as the mode of INR surveillance differed, overall quality of anticoagulation management by TTR was relatively homogenous in AF patients across countries.

Details

Original languageEnglish
Pages (from-to)833-841
Number of pages9
JournalThrombosis and Haemostasis
Volume111
Issue number5
Early online date20 Mar 2014
Publication statusPublished - May 2014

Keywords

  • Acenocoumarol, Administration, Oral, Aged, Aged, 80 and over, Anticoagulants, Atrial Fibrillation, Europe, Female, Humans, Male, Middle Aged, Phenindione, Phenprocoumon, Practice Guidelines as Topic, Registries, Vitamin K, Warfarin, Withholding Treatment, cross-sectional, INR